Escalation to weekly dosing recaptures response in adalimumab‐treated patients with moderately to severely active ulcerative colitis
Open Access
- 15 July 2014
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 40 (5), 486-497
- https://doi.org/10.1111/apt.12863
Abstract
Background Patients with moderately to severely active ulcerative colitis occasionally do not respond to or lose initial response to maintenance dosing of anti‐TNF therapy. Aim To report the efficacy of escalation from every other week (EOW) to weekly adalimumab dosing in patients from the clinical trial ULTRA 2 (NCT00408629), by week 8 response (i.e. response after adalimumab induction therapy). Methods Week 52 remission, response, and mucosal healing rates were assessed in ULTRA 2 adalimumab‐randomised patients who escalated to weekly dosing. Patients were stratified by week 8 response per partial Mayo score. Kaplan–Meier and logistic regression analyses estimated time to weekly dosing and defined predictors of escalation to weekly dosing, respectively. Adverse events were reported for patients receiving open‐label adalimumab. Results The rate of escalation to weekly dosing was 16.3% (20/123) for week 8 responders and 38.4% (48/125) for week 8 nonresponders. Week 52 remission, response and mucosal healing rates with weekly dosing were 20%, 45%, and 45% for week 8 responders and 2.1%, 25% and 29.2% for nonresponders, respectively (NRI). The median time to weekly dosing was 288 days for week 8 nonresponders and not estimable for responders. Prior anti‐TNF use was a significant predictor of escalation to weekly dosing. Treatment‐emergent adverse event rates were similar for patients receiving open‐label EOW or weekly adalimumab. Conclusions Escalation to weekly adalimumab dosing demonstrated clinical benefits for patients who lost response to therapy and may be beneficial for patients not initially responding to induction therapy. No new safety risks were identified with weekly dosing.Keywords
Funding Information
- AbbVie (None)
This publication has 20 references indexed in Scilit:
- Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative ColitisGastroenterology, 2014
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2014
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2014
- 52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or ImmunosuppressantsInflammatory Bowel Diseases, 2013
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel diseaseJournal of Crohn's and Colitis, 2011
- Assessing Response and Loss of Response to Biological Therapies in IBDThe American Journal of Gastroenterology, 2011
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut, 2011
- Importance of mucosal healing in ulcerative colitisInflammatory Bowel Diseases, 2010
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2005